Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter

Executive Summary

Wall Street's enthusiastic response to Lilly's potential sepsis therapy may represent the triumph of biotechnology - at least in terms of investor approaches to pharmaceutical stock valuations.
Advertisement

Related Content

Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling
Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling
Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.
Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.
Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit
Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit
Advertisement
UsernamePublicRestriction

Register

PS036305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel